News in brief

AstraZeneca settles generic Entocort suit

UNITED STATES

Anglo-Swedish drug maker AstraZeneca has reached a settlement with Teva Pharmaceuticals over the marketing of a generic copy of AstraZeneca’s anti-inflammatory drug Entocort (budesonide). Under the terms of the agreement, Teva will be able to sell its budesonide in the US from 15 February 2012, subject to regulatory approval ‘or earlier in certain circumstances’. No financial details have been disclosed.